CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 546 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Formula:C22H28ClFN6O4SColor and Shape:SolidMolecular weight:527.01Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPurity:98%Color and Shape:Odour SolidCDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Formula:C20H21F2N9Color and Shape:SolidMolecular weight:425.448TMX-2138
CAS:TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.Formula:C40H43BrFN9O11SColor and Shape:SolidMolecular weight:956.791CDK9 inhibitor HH1
CAS:CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.
Formula:C13H15N3OSPurity:99.92%Color and Shape:SolidMolecular weight:261.34NecroIr2
NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.Formula:C46H30ClIrN6O2Color and Shape:SolidMolecular weight:926.44XY028-133
CAS:XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.
Formula:C53H67N11O7SPurity:97.11%Color and Shape:SolidMolecular weight:1002.23CDK9-IN-25
CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.Formula:C15H16FN5Purity:98%Color and Shape:SolidMolecular weight:285.32EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99Cdk2/Cyclin Inhibitory Peptide I
CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.Formula:C111H196N48O23Purity:98%Color and Shape:SolidMolecular weight:2571.05CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Formula:C20H20BrF3N6O2Color and Shape:SolidMolecular weight:513.319CDK7-IN-21
CAS:CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor [1] .Formula:C33H36FN9O2Color and Shape:SolidMolecular weight:609.7PROTAC CDK9 degrader-11
CAS:PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)Formula:C39H48Cl2N10O5Color and Shape:SolidMolecular weight:807.768IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Formula:C23H32FN5O2SiColor and Shape:SolidMolecular weight:457.625PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Formula:C44H52Cl2N10O7Purity:98%Color and Shape:SolidMolecular weight:903.85CDK12/13-IN-2
CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.Formula:C24H22FN7O2Color and Shape:SolidMolecular weight:459.48EGFR/CDK2-IN-3
EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.Formula:C30H20N6OSPurity:98%Color and Shape:SolidMolecular weight:512.58CDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.Formula:C18H18BrCl2N5O3Color and Shape:SolidMolecular weight:503.177CDK2-IN-43
CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.Formula:C19H27N7OColor and Shape:SolidMolecular weight:369.464CDK5-IN-1
CAS:CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.Formula:C24H25FN6O3SColor and Shape:SolidMolecular weight:496.56
